Related Experiment Video
Updated: Mar 24, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Long-term antithrombotic pharmacotherapy following ST-elevation myocardial infarction
Sergio Buccheri1, Davide Capodanno
1Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy - dcapodanno@gmail.com.
Abstract:
The selection and optimal duration of pharmacological agents to counteract thrombotic processes activated in patients with ST-elevation myocardial infarction (STEMI) still remain a debated issue in current clinical practice. Recently published trials have highlighted the potential benefits of dual-antiplatelet therapy (DAPT) extended beyond the currently recommended 12-months term. Anticoagulation with non-vitamin K oral anticoagulants in addition to DAPT has also been explored. Importantly, benefits of prolonged antithrombotic management strategies could be offset by harms following bleeding complications, therefore careful assessment of a patient benefit-risk profile must be used to drive individualized medical decisions. Appraising current available evidence is useful to inform clinical practice and to optimize the pharmacological management of patients with STEMI. Accordingly, we provide an overview of the literature focusing on long-term antithrombotic management strategies in patients with a recent or prior myocardial infarction, with a primary focus on STEMI.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Myocarditis III: Medical Management
Angina IV: Management

